Exozymes Inc. (EXOZ) shareholders
Close on Nov 17, 2026Market cap $30.72MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Christopher A. Marlett Joint filing with Anthony DiGiandomenico (43.61%), MDB Capital Holdings, LLC (43.41%) | 4,155,904 | 43.61% | 13D (active) | Nov 14, 2024 |
| Tyler Korman | 832,569 | 8.74% | 13D (active) | Nov 14, 2024 |
| Paul Opgenorth | 744,333 | 7.81% | 13D (active) | Nov 14, 2024 |
| James U Bowie | 597,388 | 6.27% | 13D (active) | Nov 14, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EXOZ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 54,985 | 0.59% | $463.52K | +32,795 | 0.00% |
| Davidson Kahn Capital Management, LLC | 25,000 | 0.27% | $210.75K | New | 0.09% |
| Geode Capital Management, LLC | 23,406 | 0.25% | $197.31K | +1,515 | 0.00% |
| BlackRock, Inc. | 9,610 | 0.10% | $81.01K | +2,813 | 0.00% |
| Vanguard Fiduciary Trust Co | 9,426 | 0.10% | $79.46K | – | 0.00% |
| Morgan Stanley | 1,250 | 0.01% | $10.54K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 349 | 0.00% | $2.94K | −968 | 0.00% |
| UBS Group AG | 203 | 0.00% | $1.71K | +179 | 0.00% |
| Barclays PLC | 75 | 0.00% | $632 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 9 | 0M | 1.3% | 2 / 4 | 1 / 0 | 0M | 0M |
| Q1 2026 | 7 | 0M | 0.7% | 2 / 3 | 1 / 1 | 0M | 0M |
| Q4 2025 | 7 | 0M | 0.7% | 1 / 3 | 2 / 0 | 0M | 0M |
| Q3 2025 | 6 | 0M | 0.6% | 0 / 3 | 2 / 3 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.8% | 3 / 4 | 2 / 0 | 0M | 0M |
| Q1 2025 | 6 | 0M | 0.8% | 1 / 3 | 2 / 2 | 0M | 0M |
| Q4 2024 | 7 | 0M | 1.1% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
9 funds held EXOZ in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of EXOZ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 25,879 | 0.28% | $218.16K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 22,342 | 0.24% | $188.34K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 10,311 | 0.11% | $100.53K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 9,167 | 0.10% | $77.28K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 2,944 | 0.03% | $28.70K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,018 | 0.02% | $19.68K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 1,997 | 0.02% | $19.47K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 443 | 0.00% | $3.73K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mohammad Hayat | President & Chairman of Board, Director | 155,818 | 1.68% | Nov 18, 2024 |
| Damien Alan Perriman | Chief Commercial Officer | 28,692 | 0.31% | Oct 26, 2026 |
| Tyler Paz Korman | Chief Scientific Officer | 729,123 | 7.86% | Oct 21, 2026 |
| Fouad Nawaz | Vice President- Finance | 9,488 | 0.10% | Sep 17, 2026 |
| Michael Heltzen | Chief Executive Officer | 14,708 | 0.16% | Sep 2, 2026 |
| Paul Hideo Opgenorth | Vice President, Development | 645,149 | 6.95% | Apr 8, 2026 |
| Edgardo Javier Rayo | Director | 77,909 | 0.84% | Oct 19, 2026 |
| Anthony Digiandomenico | Director, 10% owner | 3,808,476 | 41.03% | Oct 19, 2026 |
| Lon E. Bell | Director | – | – | Oct 19, 2026 |
| Christopher A. Marlett | Director, 10% owner | 3,808,476 | 41.03% | Oct 19, 2026 |
| James Joseph Lalonde | Director | – | – | Oct 19, 2026 |
| James Ulrich Bowie | Director | 577,910 | 6.23% | Oct 19, 2026 |
| MDB Capital Holdings, LLC | 10% owner | 3,931,133 | 42.36% | Nov 18, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Damien Alan Perriman Chief Commercial Officer | Oct 12, 2026 | Sale | −3,729 | $5.21 | $19.43K | 28,692 |
| Damien Alan Perriman Chief Commercial Officer | Oct 9, 2026 | Option exercise | +3,922 | – | – | 32,421 |
| Michael Heltzen Chief Executive Officer | Aug 26, 2026 | Buy | +4 | $7.58 | $30 | 14,708 |
| Michael Heltzen Chief Executive Officer | Aug 26, 2026 | Buy | +250 | $7.60 | $1.90K | 14,453 |
| Michael Heltzen Chief Executive Officer | Aug 26, 2026 | Buy | +251 | $7.35 | $1.84K | 14,704 |
| Michael Heltzen Chief Executive Officer | Aug 25, 2026 | Buy | +250 | $7.52 | $1.88K | 14,203 |
| Michael Heltzen Chief Executive Officer | Aug 25, 2026 | Buy | +100 | $7.50 | $750 | 13,953 |
| Michael Heltzen Chief Executive Officer | Aug 19, 2026 | Award | +8,841 | $6.40 | $56.58K | 13,853 |
| Tyler Paz Korman Chief Scientific Officer | Aug 19, 2026 | Option exercise | +32,964 | – | – | 762,837 |
| Damien Alan Perriman Chief Commercial Officer | Aug 19, 2026 | Option exercise | +19,612 | – | – | 28,499 |
| Tyler Paz Korman Chief Scientific Officer | Apr 9, 2026 | Sale | −750 | $10.53 | $7.90K | 729,123 |
| Tyler Paz Korman Chief Scientific Officer | Apr 8, 2026 | Sale | −750 | $10.04 | $7.53K | 729,873 |
| Damien Alan Perriman Chief Commercial Officer | Apr 1, 2026 | Award | +62,759 | – | – | 62,759 |
| Tyler Paz Korman Chief Scientific Officer | Apr 1, 2026 | Award | +5,332 | $8.44 | $45.00K | 730,623 |
| Paul Hideo Opgenorth Vice President, Development | Apr 1, 2026 | Award | +3,999 | $8.44 | $33.75K | 645,149 |
| Damien Alan Perriman Chief Commercial Officer | Apr 1, 2026 | Award | +8,887 | $8.44 | $75.01K | 0 |
| Fouad Nawaz Vice President- Finance | Apr 1, 2026 | Award | +5,999 | $8.44 | $50.63K | 9,488 |
| Michael Heltzen Chief Executive Officer | Jul 2, 2025 | Buy | +1,040 | $10.22 | $10.63K | 10,629 |
| Tyler Paz Korman Vice President, Research | Jun 16, 2025 | Award | +2,990 | $12.54 | $37.49K | 725,291 |
| Paul Hideo Opgenorth Vice President, Development | Jun 13, 2025 | Award | +2,990 | $12.54 | $37.49K | 641,150 |
| Fouad Nawaz Vice President, Finance | Jun 13, 2025 | Award | +3,489 | $12.54 | $43.75K | 3,489 |
| Michael Heltzen Chief Executive Officer | Jan 17, 2025 | Buy | +1,767 | $10.78 | $19.05K | 3,872 |
| Michael Heltzen Chief Executive Officer | Jan 16, 2025 | Buy | +121 | $10.72 | $1.30K | 2,105 |
| Michael Heltzen Chief Executive Officer | Nov 15, 2024 | Buy | +1,984 | $11.10 | $22.02K | 1,984 |
| MDB Capital Holdings, LLC 10% owner | Nov 8, 2024 | Conversion | +122,657 | $6.40 | $785.00K | 3,931,133 |
| Paul Hideo Opgenorth Vice President, Development | Nov 8, 2024 | Conversion | +2,344 | $6.40 | $15.00K | 640,504 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Exozymes's stock actually held short. Settlement fails (shares not delivered on time) peaked at 752 shares on Sep 9, 2026 over the last 90 days.
See a number that looks wrong?